Compromise of Hsp90 or calcineurin function transforms antifungals from fungistatic to fungicidal and enhances the efficacy of antifungals in mammalian models of systemic and biofilm fungal infections [15], [22]–[24], suggesting that combination therapy with azoles and inhibitors of Hsp90 or calcineurin may provide a powerful strategy to treat life-threatening fungal infections. The gene discussed is HSP90AB1; the disease is fungal infectious disease.